
    
      The study was a randomized, double blind, placebo controlled study consisting of 2
      substudies. In substudy 1, participants received 1 of 3 doses of ABT-267 or placebo +
      pegIFN/RBV for 12 weeks. In substudy 2, participants received pegIFN/RBV for 36 weeks.
      Participants were followed for 48 weeks post ABT-267 treatment for evaluation of efficacy and
      safety.
    
  